Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP, Bănescu C, Tevet M, Bojan A, Dima D, Urian L, Török-Vistai T, Popov VM, Zdrenghea M, Petrov L, Vasilache A, Murat M, Georgescu D, Popescu M, Pătrinoiu O, Balea M, Costache R, Coleș E, Șaguna C, Berbec N, Vlădăreanu AM, Mihăilă RG, Bumbea H, Cucuianu A, Popp RA. Trifa AP, et al. Among authors: popov vm. Br J Haematol. 2016 Jul;174(2):218-26. doi: 10.1111/bjh.14041. Epub 2016 Apr 7. Br J Haematol. 2016. PMID: 27061303 Free article.
MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients.
Trifa AP, Bănescu C, Bojan AS, Voina CM, Popa Ș, Vișan S, Ciubean AD, Tripon F, Dima D, Popov VM, Vesa ȘC, Andreescu M, Török-Vistai T, Mihăilă RG, Berbec N, Macarie I, Coliţă A, Iordache M, Cătană AC, Farcaș MF, Tomuleasa C, Vasile K, Truică C, Todincă A, Pop-Muntean L, Manolache R, Bumbea H, Vlădăreanu AM, Gaman M, Ciufu CM, Popp RA. Trifa AP, et al. Among authors: popov vm. Am J Hematol. 2018 Jan;93(1):100-106. doi: 10.1002/ajh.24946. Epub 2017 Nov 10. Am J Hematol. 2018. PMID: 29047144 Free article.
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Herishanu Y, Shaulov A, Fineman R, Bašić-Kinda S, Aviv A, Wasik-Szczepanek E, Jaksic O, Zdrenghea M, Greenbaum U, Mandac I, Simkovic M, Morawska M, Benjamini O, Spacek M, Nemets A, Bairey O, Trentin L, Ruchlemer R, Laurenti L, Stanca Ciocan O, Doubek M, Shvidel L, Dali N, Mirás F, De Meûter A, Dimou M, Mauro FR, Coscia M, Bumbea H, Szász R, Tadmor T, Gutwein O, Gentile M, Scarfò L, Tedeschi A, Sportoletti P, Gimeno Vázquez E, Marquet J, Assouline S, Papaioannou M, Braester A, Levato L, Gregor M, Rigolin GM, Loscertales J, Medina Perez A, Nijziel MR, Popov VM, Collado R, Slavutsky I, Itchaki G, Ringelstein S, Goldschmidt N, Perry C, Levi S, Polliack A, Ghia P. Herishanu Y, et al. Among authors: popov vm. Am J Hematol. 2020 Jun;95(6):604-611. doi: 10.1002/ajh.25766. Epub 2020 Mar 14. Am J Hematol. 2020. PMID: 32096887 Free article. Clinical Trial.
92 results